Drug intelligence / Profile preview

WL-8713

Development stage: Phase 2
Lead developer: Allergan
Modality: Small Molecules
Administration: Topical

Overview

WL-8713 is a small molecule drug developed as an anticholinergic agent, specifically functioning as an antagonist of the acetylcholine receptor (AChR), including alpha1, beta1, delta, and gamma subunits. It was initially developed by Allergan UC. The primary indication investigated for this compound has been primary axillary hyperhidrosis (excessive underarm sweating). As of the latest available data, its highest development phase was Phase 2 clinical trials in the United States. There are no approved indications or known brand names associated with this drug.

Other names: Anticholinergic therapeutic

Targets

Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on WL-8713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WL-8713.

Explore the full profile